文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

同种异体间充质基质细胞治疗中重度急性呼吸窘迫综合征(START研究):一项随机2a期安全性试验

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
PubMed 文献 · Lancet Respir Med · 2018-11-16
一句话结论在中重度ARDS通气患者中,单次静脉输注10×10⁶/kg预测体重的骨髓来源间充质基质细胞未发生预设的MSC相关血流动力学或呼吸不良事件,但28天死亡率两组无显著差异。

START研究为前瞻性、双盲、多中心、随机2a期试验,在美国5所大学医学中心纳入需机械通气的中重度ARDS患者(PaO2/FiO2<27 kPa且PEEP≥8 cm H2O),按2:1随机接受单次静脉输注10×10⁶/kg预测体重的骨髓来源MSC或安慰剂。主要终点为安全性,未发生预设的MSC相关血流动力学或呼吸不良事件;MSC组1例在输注后24小时内死亡,判定可能与MSC无关。28天死亡率MSC组30% vs 安慰剂组15%(OR 2.4,95%CI 0.5-15.1),校正APACHE III后28天死亡HR 1.43(95%CI 0.40-5.12,p=0.58)。作者认为单次静脉MSC在中重度ARDS患者中安全,需更大规模试验评估疗效并提高MSC活力。

要点

  • 中重度ARDS通气患者(PaO2/FiO2<27 kPa且PEEP≥8 cm H2O)单次静脉输注10×10⁶/kg预测体重的骨髓来源MSC,未发生预设的MSC相关血流动力学或呼吸不良事件。
  • MSC组1例在输注后24小时内死亡,研究者判定可能与MSC无关。
  • 28天死亡率MSC组30% vs 安慰剂组15%(OR 2.4,95%CI 0.5-15.1);校正APACHE III后28天死亡HR 1.43(95%CI 0.40-5.12,p=0.58)。
  • 基线时MSC组APACHE III评分(104 vs 89)、分钟通气量(11.1 vs 9.6 L/min)和PEEP(12.4 vs 10.8 cm H2O)均值高于安慰剂组。
  • MSC活力范围为36%至85%,作者认为需提高MSC活力并开展更大规模试验评估疗效。

适用人群与场景

  • 美国5所大学医学中心收治的需机械通气的中重度ARDS患者,纳入标准为PaO2/FiO2<27 kPa且PEEP≥8 cm H2O。
  • 排除年龄小于18岁、创伤或中重度肝病患者,以及既往2年内接受过癌症治疗的患者。

诊断标准与关键阈值

  • 中重度ARDS诊断标准:PaO2/FiO2<27 kPa且PEEP≥8 cm H2O,并需机械通气。

处置流程与药物剂量

  • MSC组:单次静脉输注10×10⁶/kg预测体重的骨髓来源间充质基质细胞。
  • 安慰剂组:单次静脉输注安慰剂。
  • 随机化按2:1分配,采用计算机生成序列、可变区组设计并按中心分层。

红旗征与不能漏的情况

  • MSC组1例在输注后24小时内死亡,研究者判定可能与MSC无关。

研究设计与关键结果

  • 研究类型:前瞻性、双盲、多中心、随机2a期安全性试验;样本量60例(MSC组40例,安慰剂组20例),来自美国5所大学医学中心。
  • 主要终点安全性:无患者发生预设的MSC相关血流动力学或呼吸不良事件。
  • 28天死亡率:MSC组30% vs 安慰剂组15%,OR 2.4(95%CI 0.5-15.1)。
  • 校正APACHE III评分后28天死亡HR 1.43(95%CI 0.40-5.12,p=0.58)。
  • 基线APACHE III评分MSC组104(SD 31)vs 安慰剂组89(SD 33);分钟通气量MSC组11.1(SD 3.2)L/min vs 安慰剂组9.6(SD 2.4)L/min;PEEP MSC组12.4(SD 3.7)cm H2O vs 安慰剂组10.8(SD 2.6)cm H2O。
  • 事后分析显示MSC活力范围为36%至85%。

证据类型、等级与局限

  • 证据类型:随机、双盲、多中心2a期安全性试验。
  • 作者结论:单次静脉MSC在中重度ARDS患者中安全;需更大规模试验评估疗效,且必须提高MSC活力。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为单次静脉输注10×10⁶/kg预测体重的骨髓来源MSC在中重度ARDS患者中安全,但需更大规模试验评估疗效并提高MSC活力。
  • 该研究为2a期安全性试验,未显示28天死亡率获益(MSC组30% vs 安慰剂组15%,OR 2.4,95%CI 0.5-15.1)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety has not been established for administration of MSCs in critically ill patients with ARDS. We did a phase 2a trial to assess safety after administration of MSCs to patients with moderate to severe ARDS.

METHODS: We did a prospective, double-blind, multicentre, randomised trial to assess treatment with one intravenous dose of MSCs compared with placebo. We recruited ventilated patients with moderate to severe ARDS (ratio of partial pressure of oxygen to fractional inspired oxygen <27 kPa and positive end-expiratory pressure [PEEP] ≥8 cm H2O) in five university medical centres in the USA. Patients were randomly assigned 2:1 to receive either 10 × 106/kg predicted bodyweight MSCs or placebo, according to a computer-generated schedule with a variable block design and stratified by site. We excluded patients younger than 18 years, those with trauma or moderate to severe liver disease, and those who had received cancer treatment in the previous 2 years. The primary endpoint was safety and all analyses were done by intention to treat. We also measured biomarkers in plasma. MSC viability was tested in a post-hoc analysis. This trial is registered with ClinicalTrials.gov, number NCT02097641.

FINDINGS: From March 24, 2014, to Feb 9, 2017 we screened 1038 patients, of whom 60 were eligible for and received treatment. No patient experienced any of the predefined MSC-related haemodynamic or respiratory adverse events. One patient in the MSC group died within 24 h of MSC infusion, but death was judged to be probably unrelated. 28-day mortality did not differ between the groups (30% in the MSC group vs 15% in the placebo group, odds ratio 2·4, 95% CI 0·5-15·1). At baseline, the MSC group had numerically higher mean scores than the placebo group for Acute Physiology and Chronic Health Evaluation III (APACHE III; 104 [SD 31] vs 89 [33]), minute ventilation (11·1 [3·2] vs 9·6 [2·4] L/min), and PEEP (12·4 [3·7] vs 10·8 [2·6] cm H2O). After adjustment for APACHE III score, the hazard ratio for mortality at 28 days was 1·43 (95% CI 0·40-5·12, p=0·58). Viability of MSCs ranged from 36% to 85%.

INTERPRETATION: One dose of intravenous MSCs was safe in patients with moderate to severe ARDS. Larger trials are needed to assess efficacy, and the viability of MSCs must be improved.

FUNDING: National Heart, Lung, and Blood Institute.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2018. PMID: 30455077. doi:10.1016/S2213-2600(18)30418-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。